We are live on ! Find out more
QTTB icon

Q32 Bio

86 hedge funds and large institutions have $756M invested in Q32 Bio in 2019 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 27 increasing their positions, 22 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 2 → 4 (+2)

100% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 8

23% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 22

11.44% more ownership

Funds ownership: 71.47% → 82.91% (+11%)

8% more funds holding

Funds holding: 80 → 86 (+6)

19% less capital inflows, than outflows

Capital inflows: $47.6M | Capital outflows: $58.7M

97% less call options, than puts

Call options by funds: $28K | Put options by funds: $924K

Holders
86
Holders Change
+6
Holders Change %
+7.5%
% of All Funds
1.69%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.08%
New
16
Increased
27
Reduced
22
Closed
8
Calls
$28​K
Puts
$924​K
Net Calls
-⁠$896​K
Net Calls Change
-⁠$920​K

QTTB Hedge Fund Activity: Q4 2019 in Review

86 of the 5,090 institutional investors tracked by Wall St. Rank reported a position in Q32 Bio (QTTB) for Q4 2019, worth a combined $756M — up 33% from $569M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new QTTB positions and 8 closed out — a net gain of 8 holders — while 27 added to existing stakes and 22 trimmed.

The largest buyer was RTW Investments, adding an estimated $30.2M. The largest seller was Casdin Capital, exiting entirely with an estimated $14.8M sold.

  • 86 institutional investors held Q32 Bio (QTTB) as of Q4 2019, up from 80 in Q3 2019.
  • Funds reported $756M of Q32 Bio stock for Q4 2019, up 33% quarter-over-quarter.
  • 16 funds opened new Q32 Bio positions in Q4 2019 and 8 closed out, a net change of +8 holders.
  • The largest Q32 Bio buyer in Q4 2019 was RTW Investments, an estimated $30.2M added.
  • The largest Q32 Bio seller in Q4 2019 was Casdin Capital, an estimated $14.8M sold.

Based on aggregated 13F filings for Q4 2019.